View ValuationCopley Acquisition 将来の成長Future 基準チェック /06現在、 Copley Acquisitionの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Capital Markets 収益成長11.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 12Ignite Proteomics LLC entered into a definitive business combination agreement to acquire Copley Acquisition Corp (NYSE:COPL) from Copley Acquisition Sponsors, LLC and others for approximately $160 million in a reverse merger transaction.Ignite Proteomics LLC entered into a definitive business combination agreement to acquire Copley Acquisition Corp (NYSE:COPL) from Copley Acquisition Sponsors, LLC and others for approximately $160 million in a reverse merger transaction on June 10, 2026. The aggregate consideration to be paid to holders of Ignite’s membership interests as of the Effective Time (collectively, the “ Sellers ”) pursuant to the Company Merger shall consist of a number of newly issued shares of Pubco Common Stock equal to One Hundred and Fifty Million U.S. Dollars ($150,000,000) divided by Ten U.S. Dollars ($10.00) (the “ Merger Consideration ”). The transaction implies an enterprise value of $150 million for Ignite Proteomics. Upon completion, Ignite will merge with a subsidiary of a newly formed public company, Ignite Proteomics Holdings, Inc. ("Pubco"), and will become a wholly-owned subsidiary of Pubco. Copley Acquisition Corp. will also merge into a subsidiary of Pubco, with Pubco becoming the new publicly traded entity. The Parties shall take all necessary action, including causing the directors of the Pubco to resign, so that effective as of the Closing, Pubco’s board of directors (the “ Post-Closing Pubco Board ”) will consist of seven (7) individuals. Immediately after the Closing, the Parties shall take all necessary action to designate and appoint to the Post-Closing Pubco Board those persons designated by the Company prior to the Closing (the “ Company Directors ”), at least four (4) of whom shall be required to qualify as an independent director under NYSE rules and one (1) of whom shall be the chief executive officer of the Company. The obligations of the parties to consummate the Transactions are subject to various conditions, including the following mutual conditions of the parties, unless waived: (i) the approval of the Business Combination Agreement and the Transactions and related matters by the requisite vote of each of Copley’s shareholders and Ignite’s members; (ii) the expiration or termination of any waiting period applicable to the consummation of the Business Combination Agreement under any antitrust laws; (iii) obtaining material regulatory approvals; (iv) obtaining or making the Consents required to be obtained from or made with third Persons; (v) no law or order preventing or prohibiting the Transactions; (vi) appointment of the Post-Closing Pubco Board consistent with the requirements of the Business Combination Agreement; (vii) the effectiveness of the Registration Statement; (viii) the Conversion shall have been consummated; (ix) Pubco shall have amended and restated its certificate of incorporation in a form satisfactory to Copley and Ignite; (x) shares of Pubco Common Stock and Pubco Public Warrants shall have been approved for listing on the NYSE upon the Closing. The transaction has been approved by the board of directors of Copley Acquisition and Ignite Proteomics. Clear Street LLC is acting as the financial advisor to Copley. Mike Blankenship of Winston Taylor LLP is acting as legal counsel to Copley. Ladenburg Thalmann & Co. Inc. is acting as the financial advisor to Ignite Proteomics. Louis Lombardo of Meister Seelig & Schuster PLLC is acting as legal counsel to Ignite Proteomics.お知らせ • May 17Copley Acquisition Corp announced delayed 10-Q filingOn 05/15/2026, Copley Acquisition Corp announced that they will be unable to file their next 10-Q by the deadline required by the SEC.New Risk • Apr 02New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Negative equity (-US$44k). Revenue is less than US$1m. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Copley Acquisition は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NYSE:COPL - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026N/A5-1-1N/A12/31/2025N/A400N/Aアナリストによる今後の成長予測収入対貯蓄率: COPLの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: COPLの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: COPLの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: COPLの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: COPLの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: COPLの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YDiversified-financials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/18 11:09終値2026/06/18 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Copley Acquisition Corp 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 12Ignite Proteomics LLC entered into a definitive business combination agreement to acquire Copley Acquisition Corp (NYSE:COPL) from Copley Acquisition Sponsors, LLC and others for approximately $160 million in a reverse merger transaction.Ignite Proteomics LLC entered into a definitive business combination agreement to acquire Copley Acquisition Corp (NYSE:COPL) from Copley Acquisition Sponsors, LLC and others for approximately $160 million in a reverse merger transaction on June 10, 2026. The aggregate consideration to be paid to holders of Ignite’s membership interests as of the Effective Time (collectively, the “ Sellers ”) pursuant to the Company Merger shall consist of a number of newly issued shares of Pubco Common Stock equal to One Hundred and Fifty Million U.S. Dollars ($150,000,000) divided by Ten U.S. Dollars ($10.00) (the “ Merger Consideration ”). The transaction implies an enterprise value of $150 million for Ignite Proteomics. Upon completion, Ignite will merge with a subsidiary of a newly formed public company, Ignite Proteomics Holdings, Inc. ("Pubco"), and will become a wholly-owned subsidiary of Pubco. Copley Acquisition Corp. will also merge into a subsidiary of Pubco, with Pubco becoming the new publicly traded entity. The Parties shall take all necessary action, including causing the directors of the Pubco to resign, so that effective as of the Closing, Pubco’s board of directors (the “ Post-Closing Pubco Board ”) will consist of seven (7) individuals. Immediately after the Closing, the Parties shall take all necessary action to designate and appoint to the Post-Closing Pubco Board those persons designated by the Company prior to the Closing (the “ Company Directors ”), at least four (4) of whom shall be required to qualify as an independent director under NYSE rules and one (1) of whom shall be the chief executive officer of the Company. The obligations of the parties to consummate the Transactions are subject to various conditions, including the following mutual conditions of the parties, unless waived: (i) the approval of the Business Combination Agreement and the Transactions and related matters by the requisite vote of each of Copley’s shareholders and Ignite’s members; (ii) the expiration or termination of any waiting period applicable to the consummation of the Business Combination Agreement under any antitrust laws; (iii) obtaining material regulatory approvals; (iv) obtaining or making the Consents required to be obtained from or made with third Persons; (v) no law or order preventing or prohibiting the Transactions; (vi) appointment of the Post-Closing Pubco Board consistent with the requirements of the Business Combination Agreement; (vii) the effectiveness of the Registration Statement; (viii) the Conversion shall have been consummated; (ix) Pubco shall have amended and restated its certificate of incorporation in a form satisfactory to Copley and Ignite; (x) shares of Pubco Common Stock and Pubco Public Warrants shall have been approved for listing on the NYSE upon the Closing. The transaction has been approved by the board of directors of Copley Acquisition and Ignite Proteomics. Clear Street LLC is acting as the financial advisor to Copley. Mike Blankenship of Winston Taylor LLP is acting as legal counsel to Copley. Ladenburg Thalmann & Co. Inc. is acting as the financial advisor to Ignite Proteomics. Louis Lombardo of Meister Seelig & Schuster PLLC is acting as legal counsel to Ignite Proteomics.
お知らせ • May 17Copley Acquisition Corp announced delayed 10-Q filingOn 05/15/2026, Copley Acquisition Corp announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
New Risk • Apr 02New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Negative equity (-US$44k). Revenue is less than US$1m.